Perclose wins approval for closure technique:
This article was originally published in Clinica
The US FDA has approved Perclose's minimally-invasive system for the closure of arterial access sites following catheterisation procedures. The Prostar Systems were granted expedited review. Results of clinical trials submitted in support of the PMA application compared the Perclose systems, which are used in conjunction with anticoagulant and anti-platelet drug therapies, with conventional mechanical compression for site closure.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.